Randomized Trialhigh evidence
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
The New England journal of medicine·October 3, 2024·PMID 38912654
Why it mattersThis is the first large RCT showing a pharmacologic agent can substantially reduce OSA severity in obese patients, offering a potential alternative or adjunct to PAP therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled